$330 Million is the total value of CHI Advisors LLC's 26 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PLRX | Buy | PLIANT THERAPEUTICS INC | $56,480,348 | -29.3% | 3,117,017 | +3.8% | 17.14% | -19.1% |
| New | ACELYRIN INC | $55,673,548 | – | 2,663,806 | +100.0% | 16.89% | – | |
| VECT | Sell | VECTIVBIO HLDG AG | $46,945,093 | +5.0% | 2,782,756 | -47.1% | 14.24% | +20.0% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $36,736,673 | +7.2% | 3,414,189 | +1.9% | 11.15% | +22.5% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $31,726,606 | +7.5% | 2,998,734 | +0.0% | 9.63% | +22.9% |
| KROS | Buy | KEROS THERAPEUTICS INC | $16,157,101 | +44.9% | 402,118 | +54.0% | 4.90% | +65.7% |
| IKNA | Buy | IKENA ONCOLOGY INC | $13,920,582 | +142.9% | 2,122,040 | +27.8% | 4.22% | +177.7% |
| CMPX | COMPASS THERAPEUTICS INC | $8,998,484 | -2.8% | 2,829,712 | 0.0% | 2.73% | +11.2% | |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $8,720,383 | -29.9% | 3,414,468 | +24.3% | 2.65% | -19.9% |
| Sell | 2SEVENTY BIO INC | $8,622,311 | -1.1% | 852,007 | -0.4% | 2.62% | +13.0% | |
| INZY | Sell | INOZYME PHARMA INC | $6,656,301 | -13.5% | 1,195,027 | -11.0% | 2.02% | -1.1% |
| OMEGA THERAPEUTICS INC | $5,912,938 | -7.1% | 1,055,882 | 0.0% | 1.79% | +6.2% | ||
| New | DISC MEDICINE INC | $5,556,172 | – | 125,139 | +100.0% | 1.69% | – | |
| LABD | New | DIREXION SHS ETF TRdaily s&p biotec | $4,670,250 | – | 325,000 | +100.0% | 1.42% | – |
| Sell | ORCHARD THERAPEUTICS PLCspon ads new | $3,937,394 | -6.7% | 755,738 | -3.8% | 1.20% | +6.7% | |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $3,921,050 | – | 85,000 | +100.0% | 1.19% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $3,787,500 | – | 750,000 | +100.0% | 1.15% | – |
| Sell | RALLYBIO CORP | $3,072,101 | -29.3% | 542,774 | -28.6% | 0.93% | -19.2% | |
| OVID | OVID THERAPEUTICS INC | $2,836,616 | +27.1% | 864,822 | 0.0% | 0.86% | +45.4% | |
| SYROS PHARMACEUTICALS INC | $2,417,452 | +18.0% | 767,445 | 0.0% | 0.73% | +34.9% | ||
| DTIL | Sell | PRECISION BIOSCIENCES INC | $843,471 | -67.7% | 1,603,557 | -53.8% | 0.26% | -63.1% |
| HOOK | New | HOOKIPA PHARMA INC | $694,091 | – | 788,740 | +100.0% | 0.21% | – |
| GRPH | New | GRAPHITE BIO INC | $600,439 | – | 230,938 | +100.0% | 0.18% | – |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $458,000 | -78.5% | 200,000 | -91.5% | 0.14% | -75.4% |
| PLRX | New | PLIANT THERAPEUTICS INCcall | $161,828 | – | 130,300 | +100.0% | 0.05% | – |
| New | FREELINE THERAPEUTICS HLDGSsponsored ads | $55,898 | – | 21,666 | +100.0% | 0.02% | – | |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INCcall | $0 | – | -25,000 | -100.0% | -0.03% | – |
| ONCR | Exit | ONCORUS INC | $0 | – | -2,367,436 | -100.0% | -0.22% | – |
| Exit | ENTRADA THERAPEUTICS INC | $0 | – | -56,374 | -100.0% | -0.22% | – | |
| FRLN | Exit | FREELINE THERAPEUTICS HLDGSsponsored ads | $0 | – | -4,729,419 | -100.0% | -0.57% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -689,451 | -100.0% | -0.57% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -135,000 | -100.0% | -0.83% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -934,135 | -100.0% | -26.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-08-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.